Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Materials Horizons|July 5, 2023
Constructing abundant interfaces by decorating MoP quantum dots on CoP nanowires to induce electronic structure modulation for enhanced hydrogen evolution reactionYuanyuan Chen, Tingting Sui, Chaojie Lyu, et al.
Vaccines|January 21, 2023
Acceptance and Preference for COVID-19 Vaccine among Japanese Residents at Early Stage of the Epidemic in JapanJiwen Wu, Guoxi Cai, Yi Fan, et al.
Breast (Edinburgh, Scotland)|February 8, 2022
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trialPaul Cottu, Alistair Ring, Hikmat Abdel-Razeq, et al.
Breast Cancer Research and Treatment|February 25, 2022
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trialMario Campone, Michelino De Laurentiis, Claudio Zamagni, et al.
European Urology|September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION TrialAndrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
Human Vaccines & Immunotherapeutics|March 22, 2024
Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, JapanGuoxi Cai, Shiwen Liu, Yixiao Lu, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2024
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerYen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, et al.
Pageof 3